Story perspectives

Eli Lilly's Retatrutide Meets Endpoint, Cuts Weight 28%

5/22/2026

Summary

Lilly Achieves Weight-Loss?

Eli Lilly reported retatrutide met the primary endpoint in the TRIUMPH-1 trial of 2,339 adults.
The 12 mg dose cut weight by 28.3% (70.3 pounds) over 80 weeks, with >45% losing >=30% and 37.5% of participants with baseline BMI >= 40 falling below 30.
Common side effects were nausea, vomiting and diarrhea; dysesthesia affected 12.5% and urinary-tract infections up to 9%, discontinuation 11% versus 4.9% placebo, with Lilly planning to seek FDA approval next year.

Summary

Lilly Targets FDA

Eli Lilly’s stock rose more than 2% from the opening price after the trial results were announced.
The company said it could file an FDA application as early as this year, targeting submission before year-end.
Trial data showed significant increases in HDL cholesterol, lower triglycerides and reduced systolic blood pressure versus placebo.
Researchers noted that about 10% of patients are GLP-1 non-responders, positioning retatrutide to address that unmet need.

Summary

Lilly Disputes FDA

Eli Lilly is contesting the FDA’s 2024 classification of retatrutide as a traditional drug rather than a biologic.
The dispute centers on the number of amino acids in retatrutide’s molecular structure.
Physicians warned that trial news prompted some Americans to order unregulated knockoff retatrutide from China, raising safety concerns.
Trial participants also reported a marked reduction in osteoarthritic pain, an additional benefit noted by the company.

1 of 3

Lilly Achieves Weight-Loss?

Eli Lilly reported retatrutide met the primary endpoint in the TRIUMPH-1 trial of 2,339 adults.
The 12 mg dose cut weight by 28.3% (70.3 pounds) over 80 weeks, with >45% losing >=30% and 37.5% of participants with baseline BMI >= 40 falling below 30.
Common side effects were nausea, vomiting and diarrhea; dysesthesia affected 12.5% and urinary-tract infections up to 9%, discontinuation 11% versus 4.9% placebo, with Lilly planning to seek FDA approval next year.

1 / 3